Vitality Unleashed: The Functional Medicine Podcast

Smart Missiles vs Prostate Cancer: Why “Castration‑Resistant” No Longer Means Game Over

• Dr. Kumar from LifeWellMD.com • Season 1 • Episode 221

Share episode

Send us a text

In this episode, we rewrite one of the scariest phrases in men’s health: castration‑resistant prostate cancer. Instead of a dead end, it is now a signal to change strategy—not to give up. Drawing on landmark research from late 2024 and 2025, we unpack three new pillars of hope: PSMA‑targeted “smart missile” radioligand therapy like Pluvicto, precision genetic drugs that cut the cancer’s escape lines, and powerful immunotherapy combinations that can even help men with aggressive liver metastases stay in the fight longer.​
​

You will learn how PSMA PET scans turn the whole body into a high‑resolution map, how lutetium‑177 smart missiles hunt and destroy cancer cells while sparing most healthy tissue, and what trials like CONTACT‑02 are revealing about turning “cold” tumors “hot” so the immune system finally sees the enemy. Just as important, we talk about the hidden side effect of all this progress: analysis paralysis. With so many options—radioligands, PARP inhibitors, genetic testing, immunotherapy—most men cannot and should not try to Google their way through it alone.
​​

As a board‑certified radiation oncologist, functional medicine physician, and Harvard‑trained medical acupuncturist, Dr. Ramesh Kumar explains why you now need a quarterback as much as you need a drug: someone who understands both the high‑tech cancer weapons and the metabolic “launch pad” your body needs to tolerate them. If you or someone you love is staring at a castration‑resistant diagnosis and feeling that icy sense of finality, this conversation is your playbook for the next move—and a reminder that today’s toolbox is fuller than ever before.​


Disclaimer:
The information provided in this podcast is for educational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional before making changes to your supplement regimen or health routine. Individual needs and reactions vary, so it’s important to make informed decisions with the guidance of your physician.

Connect with Us:
If you enjoyed today’s episode, be sure to subscribe, leave us a review, and share it with someone who might benefit. For more insights and updates, visit our website at Lifewellmd.com.

Stay Informed, Stay Healthy:
Remember, informed choices lead to better health. Until next time, be well and take care of yourself.

SPEAKER_00:

You know, there's a specific moment we need to talk about today. It's that moment you're in a doctor's office and a few words just hang in the air and seem to suck all the oxygen out of the room.

SPEAKER_01:

Aaron Powell It's the vocabulary of fear. You hear stage four, you might hear metastatic, but the one that really feels like you've just hit a solid brick wall is castration-resistant prostate cancer.

SPEAKER_00:

Aaron Powell Yeah, that term resistant. It sounds so final, like a door just slammed shut.

SPEAKER_01:

It does. And historically, that feeling, it was pretty justified. It means the main tool in our toolbox, which is hormone therapy to starve the cancer of testosterone, has stopped working.

SPEAKER_00:

The cancer has gotten smart.

SPEAKER_01:

It's figured out a workaround. And for a long time, the road after that got very short, and it pretty much just pointed towards chemotherapy.

SPEAKER_00:

Right. A dead end. But that's exactly why we're doing this deep dive today in January of 2026. Because that whole narrative, it's completely out of date.

SPEAKER_01:

Out of date, it's putting it mildly. The script has been totally flipped. We're looking at a huge pile of research from late 2024 and all through 2025. That changes everything.

SPEAKER_00:

Aaron Powell So this isn't just a medical lecture. We want this to be an empowerment session. The goal is to really debunk that idea that resistance means you're out of options.

SPEAKER_01:

Exactly. Because we now have these three massive pillars of hope. We've got smart missiles, we have ways to cut the cancer's genetic break lines, and we can even get the immune system to wake up and fight.

SPEAKER_00:

Aaron Powell But with all these new options comes complexity. Right. Right? That's the catch.

SPEAKER_01:

Aaron Powell It is. I mean it's a web of choices now. Radioligans, PRP inhibitors, PSMA, PE scans, genetic tests. It can lead to total analysis paralysis.

SPEAKER_00:

Aaron Ross Powell You just don't know where to start.

SPEAKER_01:

Aaron Ross Powell Exactly. And you can't just Google your way through it. You really you need a navigator, a guide.

SPEAKER_00:

Which is a perfect time to talk about the resource we're highlighting today. We're talking about Dr. Ramesh T. Kumar at LifeWell MD.

SPEAKER_01:

Dr. Kumar is a really unique figure in this field. He's kind of a unicorn because he combines disciplines that usually stay in separate silos.

SPEAKER_00:

Aaron Powell Okay, unicorn, how so?

SPEAKER_01:

Well, first, he's a board-certified radiation oncologist. So he deeply understands the high-tech nuclear medicine side of these new treatments we're about to get into.

SPEAKER_00:

But he's not just looking at the tumor.

SPEAKER_01:

No, and that's the key. He's also a functional medicine expert and was trained in medical acupuncture at Harvard. So he's looking at the patient's whole body, the metabolic terrain, so to speak.

SPEAKER_00:

The idea being that you need a strong body to handle these powerful treatments.

SPEAKER_01:

Precisely. It's about treating the whole person, not just the cancer. An integrative approach. We'll talk more about him later, but keep that idea of a quarterback in mind as we dive into the first big breakthrough, radiolitherapy.

SPEAKER_00:

Right. Specifically the drug pluvicto.

SPEAKER_01:

Pluvicto. It's a game changer. And the best way to think about it is to stop thinking about carpet bombing.

SPEAKER_00:

Like chemo.

SPEAKER_01:

Right. This is more like a sniper shot. The smart missile analogy is perfect.

SPEAKER_00:

Okay, so break it down for us. How does the missile find its target?

SPEAKER_01:

So advanced prostate cancer cells have this protein on their surface called PSMA. Think of it like a little red flag the cancer cell is waving.

SPEAKER_00:

It's basically announcing where it is.

SPEAKER_01:

It is. And plevicto is a molecule designed to be a heat-seeking missile for that flag. The first part, the ligand, is the homing device. It hunts down PSMA anywhere in the body. Bones, lymph nodes, liver. It doesn't matter.

SPEAKER_00:

And it's carrying a payload.

SPEAKER_01:

It's carrying a tiny radioactive backpack, litetium-177. It binds to the cell, gets inside, and releases a very short burst of radiation. So short that it kills the cancer cell with a without damaging most of the healthy cells around it, you're nuking the target, not the whole neighborhood.

SPEAKER_00:

That's incredible. But the really big news isn't just how it works, it's when we can use it now. Yeah. Because of the PSMA4 trial.

SPEAKER_01:

Yes. This was the study that changed the standard of care. Because for a long time, plevicto was saved for the end of the line. You had to fail chemo first.

SPEAKER_00:

Which never made a lot of sense. Why wait until the patient is exhausted to bring out your best weapon?

SPEAKER_01:

Exactly. So the PSMA 4 trial asked, what if we use it before chemo? Right after a patient's hormone pills stop working.

SPEAKER_00:

And the results were staggering.

SPEAKER_01:

They compared pluvicto to just switching to another hormone pill, which was the old way. And pluvicto more than doubled the time before the cancer started growing again.

SPEAKER_00:

I have the numbers right here. It was what, 11.6 months of progression-free survival for the plevicto group?

SPEAKER_01:

Compared to just 5.59 months for the group that just swapped pills.

SPEAKER_00:

Wow. That's not just a few extra weeks. That's half a year of extra time, of quality time, without needing to jump to chemotherapy.

SPEAKER_01:

Think of what that means holidays, birthdays, just living. It's a huge shift in the treatment paradigm.

SPEAKER_00:

Okay, that's a massive pillar of hope right there. Yeah. But let's pivot to the second one because this gets into genetics. Let's talk about PRP inhibitors and this break line analogy.

SPEAKER_01:

Yes. This is a concept called synthetic lethality. Sounds like a movie title, I know.

SPEAKER_00:

It does sound very sci-fi.

SPEAKER_01:

But the biology is it's just brilliant. So imagine a cancer cell is a car speeding down a highway. It's growing so fast its DNA is constantly getting damaged. So it needs repair crews to fix that DNA. One of its main repair crews involves genes we hear a lot about, like BRCA1 and BRCA2.

SPEAKER_00:

The same genes involved in breath cancer.

SPEAKER_01:

The very same. And it turns out that up to 30% of men with advanced prostate cancer have a mutation, a defect, in one of those genes. Their main repair crew is already broken.

SPEAKER_00:

So the car is driving, but one of its repair systems is down.

SPEAKER_01:

Exactly. But the cancer cell has a backup plan. It has a backup repair crew, an enzyme called PRP. As long as PRP is working, the car can stay on the road.

SPEAKER_00:

So here's where the inhibitor comes in.

SPEAKER_01:

Right. A PRP inhibitor, drug-like near a prib or OLAP rib, comes in and it basically fires the backup crew. It blocks PRP.

SPEAKER_00:

So now the main repair crew is broken and you've just knocked out the backup.

SPEAKER_01:

And the car crashes. The cancer cell gets so much DNA damage it can't fix and it dies. That's synthetic lethality. You're exploiting a weakness that's already there.

SPEAKER_00:

Aaron Powell And we saw this play out in the AmpliTude trial, right?

SPEAKER_01:

We did. At ASCO 2025, they showed that for men who have these specific genetic mutations, adding a PRP inhibitor to their standard therapy significantly slows the cancer's growth.

SPEAKER_00:

Aaron Powell So the So what here? The takeaway for someone listening.

SPEAKER_01:

Aaron Powell The takeaway is that genetic testing is no longer optional. It is absolutely mandatory for advanced disease. You need to know if you have one of these mutations.

SPEAKER_00:

Aaron Powell And that's both types of testing germline and somatic.

SPEAKER_01:

Yes. You need to test your inherited DNA from a blood or saliva test, and you need to test the tumor's own DNA from a biopsy. Because if you have that mutation, it unlocks this entire class of drugs. If you don't test, you're flying blind.

SPEAKER_00:

Okay. So we have smart missiles for guys whose tumors have that PSMA flag. We have brake line cutters for guys with the right genetic profile. What about the really tough cases when the cancer spreads to the liver or lungs?

SPEAKER_01:

Yeah, visceral metastases. Those have always been very, very tough. These tumors are often immunologically cold.

SPEAKER_00:

Cold, meaning the immune system just doesn't see them. It's invisible.

SPEAKER_01:

Completely invisible. But this is where our third pillar comes from: a trial called Contact Zero 2. This was published in the Lancet Oncology in mid-2025.

SPEAKER_00:

And what did they try here?

SPEAKER_01:

They used a bold combination. A drug called Cabozentinib with an immunotherapy drug, the Tesalazumeb.

SPEAKER_00:

So Cabocentinib, that's a TKI. How does that work?

SPEAKER_01:

Think of CABO as changing the tumor's neighborhood. It messes with its blood supply, but it also seems to remodel the area around the tumor, making it less hostile to immune cells. It's trying to turn that cold tumor hot.

SPEAKER_00:

So it's basically putting up a giant neon sign pointing to the cancer.

SPEAKER_01:

Aaron Powell Exactly. It primes the battlefield. And then a tesalazumab, which is a checkpoint inhibitor, comes in and takes the brakes off your immune system's T cells. It unleashes the soldiers.

SPEAKER_00:

And for that really high-risk group, did it work?

SPEAKER_01:

It did. The data showed a significant improvement in progression-free survival, especially for the patients with liver metastases, which is a group that traditionally has a very poor prognosis. It proved we can find ways to buy them time.

SPEAKER_00:

Aaron Powell So we're just layering options now. It's not one door anymore.

SPEAKER_01:

Aaron Powell That's the key. It's not just chemo or bust. Now it's the PSMA door, the PRP door, the immunocombo door. But this brings us right back to the problem we started with.

SPEAKER_00:

Analysis paralysis.

SPEAKER_01:

It's the side effect of all this amazing progress. If you're a patient, you're sitting there thinking, do I need a PSMA PT scan? Do I need a genetic test? Should I be looking for this context CR2 combo? It's completely overwhelming.

SPEAKER_00:

And a standard oncologist might just stick to the old protocol. Hormones failed. Time for chemo.

SPEAKER_01:

It can happen. Which is why having that quarterback is so vital. And this is where Dr. Tumar's integrative approach at Life Well MD really shines. Because these treatments, let's take Clovicto, it's systemic radiation. It's tough on the body.

SPEAKER_00:

It can affect your bone marrow.

SPEAKER_01:

It can. And if your blood counts, your platelets or white cells drop too low, you can't get your next dose. The treatment stops.

SPEAKER_00:

So you can't just prescribe the missile. You have to make sure the launch pad is strong.

SPEAKER_01:

That's a perfect way to put it. The functional medicine side of the practice focuses on that. Supporting bone marrow health, managing inflammation, using nutrition and other tools to keep the body robust enough to tolerate these powerful therapies.

SPEAKER_00:

So it's not natural versus medical. It's using both to make the high-tech stuff work better.

SPEAKER_01:

It's about helping the patient stay in the fight longer and with a better quality of life.

SPEAKER_00:

Okay, so let's tie this all together for everyone listening. The narrative is dead. Castration resistant is not a dead end anymore.

SPEAKER_01:

Not at all. We have the data to move powerful drugs earlier. We have genetic targeting. We have new combinations for the most aggressive forms of the disease. The toolbox is full.

SPEAKER_00:

But you need a good mechanic to know which tool to use.

SPEAKER_01:

And that's the bottom line. Don't try to figure this out alone. You need an expert guide on your team.

SPEAKER_00:

So here's the direct call to action. If any of this is resonating with you, if you're feeling that paralysis, you can reach out to Dr. Ramesh T. Kumar at LifeWellMD.

SPEAKER_01:

He's based in North Palm Beach, Florida, but and this is key. He offers telehealth consultations. So you can get his expertise from anywhere. He can review your case and help you build a strategy.

SPEAKER_00:

The number to call is 561-210-9999. Again, that's 561-210-9999. And the website is lifewellmd.com.

SPEAKER_01:

Getting an expert quarterback on your team can change everything. You do not have to do this by yourself.

SPEAKER_00:

So a final thought. What should it really mean to us now?

SPEAKER_01:

It's a signal. It's not a signal of failure. It's simply a signal to change strategy. The cancer changed, so now we change our weapons. We're moving from blunt instruments to precision tools. Yeah, exactly. The pace of this technology is just incredible. What was experimental two years ago is now the standard of care. So stay curious, ask questions, and know that options exist.

SPEAKER_00:

Thanks for this deep dive today.

SPEAKER_01:

My pleasure. Take care.